Sonendo (SONX) 10-Q 12 Nov 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Registrant Name	Sonendo, Inc.
Entity Central Index Key	0001407973
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		418,049
Entity File Number	001-40988
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-5041718
Entity Address, Address Line One	26061 Merit Circle
Entity Address, Address Line Two	Suite 102
Entity Address, City or Town	Laguna Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92653
City Area Code	949
Local Phone Number	766-3636
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	SONX

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 13,096	$ 14,009
Short-term investments	4,188	32,773
Accounts receivable, net	4,445	4,790
Inventory	11,487	11,074
Prepaid expenses and other current assets	508	1,969
Current assets of discontinued operations	1,000	656
Total current assets	34,724	65,271
Property and equipment, net	691	461
Operating lease right-of-use assets	2,592	2,703
Other assets	124	128
Non-current assets of discontinued operations		9,597
Total assets	38,131	78,160
Current liabilities:
Accounts payable	686	1,142
Accrued compensation	2,008	2,413
Other accrued expenses	3,202	3,072
Operating lease liabilities	884	1,250
Current portion of term loan	10,800	24,900
Other current liabilities	1,535	1,844
Current liabilities of discontinued operations		700
Total current liabilities	19,115	35,321
Operating lease liabilities, net of current	1,570	1,423
Term loan, net of current	6,084	12,467
Other liabilities	396	530
Total liabilities	27,165	49,741
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.001 par value; authorized -10,000,000 shares; issued and outstanding - none
Common stock, $0.001 par value; authorized - 500,000,000 shares; issued and outstanding- 418,043 shares as of September 30, 2024 and 317,737 shares as of December 31, 2023	84	64
Additional paid-in-capital	462,555	458,357
Accumulated other comprehensive income	3	11
Accumulated deficit	(451,676)	(430,013)
Total stockholders' equity	10,966	28,419
Total liabilities and stockholders' equity	$ 38,131	$ 78,160

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	418,038	317,737
Common stock, shares outstanding	418,038	317,737

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue, net	$ 8,036	$ 8,163	$ 23,397	$ 25,604
Cost of sales	4,726	7,279	14,970	23,227
Gross profit	3,310	884	8,427	2,377
Operating expenses:
Selling and marketing	3,642	6,954	12,858	22,628
General and administrative	4,872	7,708	13,952	20,257
Research and development	1,588	2,787	5,345	8,478
Total operating expenses	10,102	17,449	32,155	51,363
Operation loss	(6,792)	(16,565)	(23,728)	(48,986)
Interest and other expense:
Interest expense	(1,010)	(1,649)	(4,608)	(4,778)
Other income	266	765	1,165	2,576
Total interest and other expense	(744)	(884)	(3,443)	(2,202)
Loss before income tax expense	(7,536)	(17,449)	(27,171)	(51,188)
Loss from continuing operations, net of tax	(7,536)	(17,449)	(27,171)	(51,188)
Income from discontinued operations, net of tax		469	5,508	1,147
Net loss	(7,536)	(16,980)	(21,663)	(50,041)
Other comprehensive income (net of tax):
Unrealized (loss) gain on short-term investments	5	24	(8)	55
Comprehensive loss	$ (7,531)	$ (16,956)	$ (21,671)	$ (49,986)
Net loss per share from continuing operations - basic	$ (15.77)	$ (37.01)	$ (57.18)	$ (108.93)
Net loss per share from continuing operations - diluted	(15.77)	(37.01)	(57.18)	(108.93)
Net income per share from discontinued operations - basic		0.99	11.59	2.44
Net income per share from discontinued operations - diluted		0.99	11.59	2.44
Net loss per share - basic	(15.77)	(36.02)	(45.59)	(106.49)
Net loss per share - diluted	$ (15.77)	$ (36.02)	$ (45.59)	$ (106.49)
Weighted-average shares outstanding - basic	477,857	471,427	475,188	469,934
Weighted-average shares outstanding - diluted	477,857	471,427	475,188	469,934

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance, Shares at Dec. 31, 2022		249,871
Beginning balance at Dec. 31, 2022	$ 81,955		$ 451,110	$ (61)	$ (369,094)
Employee stock plans, Shares		1,080
Stock-based compensation	1,942		1,942
Exercised of pre-funded warrants	1		1
Exercised of pre-funded warrants, Shares		5,311
Unrealized (loss) gain on short-term investments	56			56
Net loss	(15,371)				(15,371)
Ending balance, Shares at Mar. 31, 2023		256,262
Ending balance at Mar. 31, 2023	68,583		453,053	(5)	(384,465)
Beginning balance, Shares at Dec. 31, 2022		249,871
Beginning balance at Dec. 31, 2022	81,955		451,110	(61)	(369,094)
Unrealized (loss) gain on short-term investments	55
Net loss	(50,041)
Ending balance, Shares at Sep. 30, 2023		264,856
Ending balance at Sep. 30, 2023	37,780		456,921	(6)	(419,135)
Beginning balance, Shares at Mar. 31, 2023		256,262
Beginning balance at Mar. 31, 2023	68,583		453,053	(5)	(384,465)
Employee stock plans	117		117
Employee stock plans, Shares		3,490
Stock-based compensation	2,059		2,059
Exercised of pre-funded warrants, Shares		3,546
Unrealized (loss) gain on short-term investments	(25)			(25)
Net loss	(17,690)				(17,690)
Ending balance, Shares at Jun. 30, 2023		263,298
Ending balance at Jun. 30, 2023	53,044		455,229	(30)	(402,155)
Employee stock plans	(92)		(92)
Employee stock plans, Shares		1,324
Stock-based compensation	1,784		1,784
Exercised of pre-funded warrants, Shares		234
Unrealized (loss) gain on short-term investments	24			24
Net loss	(16,980)				(16,980)
Ending balance, Shares at Sep. 30, 2023		264,856
Ending balance at Sep. 30, 2023	37,780		456,921	(6)	(419,135)
Beginning balance, Shares at Dec. 31, 2023		317,737
Beginning balance at Dec. 31, 2023	28,419		458,421	11	(430,013)
Employee stock plans	(4)		(4)
Employee stock plans, Shares		3,953
Stock-based compensation	2,890		2,890
Exercised of pre-funded warrants, Shares		30,559
Unrealized (loss) gain on short-term investments	(12)			(12)
Net loss	(6,762)				(6,762)
Ending balance, Shares at Mar. 31, 2024		352,249
Ending balance at Mar. 31, 2024	24,531		461,307	(1)	(436,775)
Beginning balance, Shares at Dec. 31, 2023		317,737
Beginning balance at Dec. 31, 2023	28,419		458,421	11	(430,013)
Unrealized (loss) gain on short-term investments	(8)
Net loss	(21,663)
Ending balance, Shares at Sep. 30, 2024		418,038
Ending balance at Sep. 30, 2024	10,966		462,639	3	(451,676)
Beginning balance, Shares at Mar. 31, 2024		352,249
Beginning balance at Mar. 31, 2024	24,531		461,307	(1)	(436,775)
Employee stock plans	1		1
Employee stock plans, Shares		1,455
Stock-based compensation	703		703
Exercised of pre-funded warrants, Shares		10,468
Unrealized (loss) gain on short-term investments	(1)			(1)
Net loss	(7,365)				(7,365)
Ending balance, Shares at Jun. 30, 2024		364,172
Ending balance at Jun. 30, 2024	17,869		462,011	(2)	(444,140)
Employee stock plans	(2)		(2)
Employee stock plans, Shares		433
Stock-based compensation	630		630
Exercised of pre-funded warrants, Shares		53,433
Unrealized (loss) gain on short-term investments	5			5
Net loss	(7,536)				(7,536)
Ending balance, Shares at Sep. 30, 2024		418,038
Ending balance at Sep. 30, 2024	$ 10,966		$ 462,639	$ 3	$ (451,676)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (21,663)	$ (50,041)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	213	1,094
Amortization of intangible assets	51	498
Amortization of right-of-use lease assets	871	947
Excess and obsolete inventory provisions	341	2,917
Impairment of long-lived assets	161	3,392
Provision for bad debt	(176)	571
Stock-based compensation	4,223	5,785
Amortization of debt issuance costs	1,717	456
Accretion of available for sale securities, net	(416)	(1,831)
Gain on sale of discontinued operations	(5,703)
Changes in operating assets and liabilities:
Accounts receivable	812	(373)
Inventory	(1,187)	1,156
Prepaid expenses and other assets	2,195	5,887
Accounts payable	(489)	(3,494)
Other accrued expenses and other liabilities	(2,146)	(2,996)
Deferred revenue	227	(19)
Accrued compensation	(749)	(506)
Net cash used in operating activities	(21,718)	(36,557)
Cash flows from investing activities:
Purchases of available-for-sale securities	(4,506)	(49,978)
Proceeds from maturities of available-for-sale securities	33,498	81,800
Purchases of property and equipment	(161)	(843)
Proceeds from sale of discontinued operations, net	14,208
Net cash provided by investing activities	43,039	30,979
Cash flows from financing activities:
Principal repayments on term loan	(22,200)
Tax paid on vested stock awards under employee stock plan	(3)	(92)
Issuance of stock under employee stock plans	(3)	117
Proceeds from exercise of pre-funded warrants		1
Principal repayments on finance lease	(28)	(23)
Net cash provided by (used in) financing activities	(22,234)	3
Net decrease in cash and cash equivalents	(913)	(5,575)
Cash and cash equivalents at beginning of period	14,009	17,665
Cash and cash equivalents at end of period	13,096	12,090
Cash paid for:
Interest	2,866	4,319
Supplemental schedule of non-cash investing and financing activities:
Operating lease right-of-use assets obtained in exchange for lease liabilities	$ 858	$ 1,792

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (7,536)	$ (7,365)	$ (6,762)	$ (16,980)	$ (17,690)	$ (15,371)	$ (21,663)	$ (50,041)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Description of Business Sonendo, Inc. (the “Company” or “we” and “our”) was incorporated in June 2006 pursuant to the laws of the State of Delaware under the name Dentatek Corporation. In March 2011, the Company changed its name to Sonendo, Inc. The Company is a medical technology company that has developed and is commercializing the GentleWave System to treat tooth decay. The Company’s principal market is the United States (“U.S.”). The Company’s products include the GentleWave System, which is cleared by the U.S. Food and Drug Administration (the “FDA”) for sale in the U.S. and approved by Health Canada in Canada, along with the system’s sterilized, single-use procedure instruments (“PIs”). Basis of Presentation The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to Form 10-Q and Article 10 of SEC Regulation S-X on a consistent basis with the Company’s annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information. Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet as of December 31, 2023 included herein was derived from the audited financial statements as of that date. The results of operations included in these unaudited condensed consolidated financial statements are not necessarily indicative of the results of operations to be expected for the year, any other interim period, or for any other future annual or interim period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed, consolidated, or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on March 11, 2024. As discussed in Note 3, “Discontinued Operations”, o n March 1, 2024, the Company divested its software segment by selling substantially all assets and liabilities of TDO Software, Inc, its wholly owned subsidiary. The sale met the criteria to be accounted for as a discontinued operation as required by Accounting Standards Codification (“ASC”) 205-20. Accordingly, the financial results of the software business are reported as discontinued operations in the accompanying unaudited Condensed C onsolidated Statements of Operations and Comprehensive Loss for all periods presented. The Company's Condensed Consolidated Statements of Cash Flows include the financial results of the software business for the nine months ended September 30, 2024 and 2023. All amounts and disclosure included in the Notes to condensed consolidated financial statements reflect only the Company's continuing operations unless otherwise noted. The accompanying unaudited condensed consolidated financial statements reflect the 1-for-200 reverse split of the Company's common stock that was approved by our Board of Directors and made effective on October 18, 2024. All share and per share information herein that relates to our common stock prior to the effective date has been retroactively restated to reflect the reverse stock split. Certain line items on the condensed consolidated statements of operations and comprehensive loss and the condensed consolidated statements of cash flows are reclassified in the prior period to conform to current period presentation. Liquidity and Going Concern As of September 30, 2024, the Company had cash and cash equivalents and short-term investments of $ 17.3 million and $ 17.8 million in principal outstanding under its term loan facility. The Company has a limited operating history, and the revenue and income potential of the Company’s business and market are unproven. The Company has experienced net losses and negative cash flows from operations since its inception and as of September 30, 2024 had an accumulated deficit of $ 451.7 million . During the nine months ended September 30, 2024, the Company incurred net losses of $ 27.2 million , used $ 21.7 million of cash and cash equivalents in its continuing operations, and recognized a gain of $ 5.7 million from sale of discontinued operations. The Company will continue to incur significant costs and expenses related to its ongoing operations until it gains greater market acceptance of its products and achieves a level of revenues adequate to support its operations. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company’s ability to continue as a going concern depends on its ability to continue to commercialize its products, achieve and maintain profitable operations, as well as the adherence to conditions of the outstanding term loan as amended in March 2024 (see Note 10). Without additional financing, the Company will have insufficient liquidity to achieve further commercialization of our products and maintain compliance with our loan covenants. Due to these conditions, there is substantial doubt about the Company’s ability to continue as a going concern and, therefore, it may be unable to realize its assets and discharge its liabilities in the normal course of business. The Company has active plans to mitigate any doubt as to the Company’s ability to continue as a going concern. Specifically, the Company has been taking steps and plans to further reduce negative cash flow through additional operating expense reductions. The Company is also actively exploring financing options, including a combination of debt, equity, and non-dilutive sources. Additionally, as detailed in Note 3 and Note 10 , in March 2024, the Company closed on the sale of TDO Software, Inc. (“TDO”) and renegotiated its covenant requirements with its lender, among other terms, which resulted in the Company remitting $ 15 million of principal payments on its outstanding borrowings. Its plans are subject to inherent risks and uncertainties and there can be no assurance that its plans can be effectively implemented and, therefore, that the conditions can be effectively mitigated. The Company will require additional financing in order to fund its future expected negative cash flows. Due to its failure to comply with the continued listing standards set forth in the NYSE’s Listed Company Manual, our common stock was suspended from trading on the NYSE effective at the opening of business Eastern Standard Time on November 22, 2023. The Company commenced trading on the OTCQX on the same day. In April 2024, the Company withdrew its request to appeal and the NYSE and our common stock has been delisted from the NYSE, which may negatively impact the Company’s stockholders and the trading price and liquidity of its common stock. Over-the-counter markets are more limited than the NYSE, and it is likely that there will be significantly less liquidity in the trading of the Company’s common stock. The delisting of the Company’s common stock from the NYSE could have material adverse effects on its business, financial condition and results of operations. On June 4, 2024, the Company received notice from OTC that the Company’s common stock no longer met the Standards for Continued Qualification for the OTCQX per the OTCQX Rules for U.S. Companies section 2.1(A) because the Company’s stock bid price closed below $ 0.10 for more than 30 consecutive calendar days. The Company had a cure period of 180 calendar days to regain compliance, which expires December 2, 2024. If the Company’s bid price did not stay at or above the $ 0.10 minimum for ten consecutive trading days during the cure period, then the Company’s common stock would have been moved from OTCQX to the OTC Pink market. On June 10, 2024, the Company’s shareholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s issued shares of common stock, at a specific ratio, ranging from 1:10 to 1:200 , at the discretion of the Company’s board of directors at any time prior to the Company’s 2025 annual meeting of stockholders, with the exact ratio to be determined by the Company’s board of directors without further approval or authorization of the Company’s stockholders. In September 2024, the Board approved a 1-for-200 reverse stock split. On October 16, 2024, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-200 reverse stock split of its issued and outstanding common stock, effective as of October 18, 2024. The reverse stock split correspondingly adjusted the per share exercise price of all outstanding options and all shares underlying any of the outstanding warrants by reducing the conversion ratio for each outstanding warrant and increasing the applicable exercise price or conversion price in accordance with the terms of each outstanding warrant and based on the reverse stock split ratio. No fractional shares were issued in connection with the reverse stock split. Stockholders who are entitled to fractional shares will receive a cash payment in lieu of receiving fractional shares (after taking into account and aggregating all shares of the Company’s common stock then held by such stockholder) equal to the fractional share interest multiplied by $ 5.00 (the per share closing price of the Company’s common stock, on a post-split basis, as last reported on the OTCQX market on November 7, 2024). The reverse stock split was announced by FINRA on its OTC Daily List on November 7,2024 and took effect at the open of trading on November 8, 2024 on the OTCQX. Upon the effectiveness of the reverse stock split, the Company became compliant with OTCQX Rule 2.1(A). The number of shares of common stock authorized under the Amended and Restated Certificate of Incorporation is unchanged at 500,000,000 shares. The accompanying interim unaudited condensed financial statements reflect the 1-for-200 reverse split of our common stock. All share and per share information data herein that relates to the Company's common stock prior to the effective date has been retroactively restated to reflect the reverse stock split. On November 7, 2024, the Company received notice from the OTC that the Company’s common stock no longer met the Standards for Continued Qualification for the OTCQX per the OTCQX Rules for U.S. Companies section 2.1(B) because the Company’s market capitalization has stayed below $ 5 million for the past 30 consecutive calendar days. The Company has a cure period of 90 calendar days to regain compliance. The 90-calendar day grace period expires February 7, 2025 and at that time if the Company’s market capitalization has not stayed at or above $ 5 million for ten consecutive trading days then the Company's common stock will be removed from OTCQX and moved to the OTC Pink market. Effects of the Macroeconomic Environment The Company’s unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2024 reflect the Company’s estimates of the impact of the macroeconomic environment, including the impact of inflation and higher interest rates. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing. Operating Segments The Company previously had two operating and reportable segments: Product and Software. Following the divestiture of the software business on March 1, 2024, there were no substantial assets or operations remaining of the software segment. The software segment was reported as discontinued operations as of September 30, 2024, and is presented as such for all periods in this report. Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this exemption and, therefore, for new or revised accounting standards applicable to public companies, the Company will be subject to an extended transition period until those standards would otherwise apply to private companies.

Summary Accounting Policies and

Summary Accounting Policies and Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary Accounting Policies and Recent Accounting Pronouncements	2. Summary Accounting Policies and Recent Accounting Pronouncements The accounting policies followed by the Company are set forth in Part II, Item 8, Note 2, Summary of Accounting Policies , of the Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make informed estimates, judgements and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and disclosures in the accompanying notes, including estimates of probable losses and expenses, as of the date of the accompanying unaudited condensed consolidated financial statements. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying unaudited condensed consolidated financial statements under different assumptions or conditions. Inventory Inventory consists of finished products, work-in-process and raw materials and is valued at the lower of cost or net realizable value. Cost may include materials, labor and manufacturing overhead. Cost is determined by the first in, first out inventory method. The carrying value of inventory is reviewed for potential impairment whenever indicators suggest that the cost of inventory exceeds the carrying value and management adjusts the inventory to its net realizable value. The Company also periodically evaluates inventory for estimated losses from excess quantities and obsolescence and writes down the cost of inventory to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs of completion and disposal. Revenue Recognition Contracts with Customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five core principles to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. Revenue recorded from continuing operations is generated from sales of the GentleWave Console and related PIs and accessories and services on its GentleWave Console. The Company’s products are sold primarily in the United States and Canada directly to customers through its field sales force. Performance Obligations The Company’s performance obligations from continuing operations primarily arise from the manufacture and delivery of the GentleWave System, related PIs and accessories, and to a lesser extent, performance of service contracts on its GentleWave Consoles. Payment terms are typically on open credit terms consistent with industry practice and do not have significant financing components. Consideration may be variable based on volume. The Company considers the individual deliverables in its product offering as separate performance obligations and assesses whether each promised good or service is distinct. The total contract transaction price is determined based on the consideration expected to be received, based on the stated value in contractual arrangements or the estimated cash to be collected in no-contracted arrangements, and is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The stand-alone selling price is based on an observable price offered to other comparable customers. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary. The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company estimates related variable consideration at the point of sale, including discounts, product returns, refunds, and other similar obligations. Revenue is recognized over time when the customer simultaneously receives and consumes the benefits provided by the Company’s performance. Revenue is recognized at a point in time if the criteria for recognizing revenue over time are not met, and the Company has transferred control of the goods to the customer. Product revenue is recognized at a point in time when the Company has transferred control to the customer, which is generally when title of the goods transfers to the customer. Sales of extended service contracts are recorded as deferred revenue until such time as the standard warranty expires, which is generally up to two years from the date of sale. Service contract revenue is recognized on a straight-line basis over time consistent with the life of the related service contract in proportion to the costs incurred in fulfilling performance obligations under the service contract. The Company generally does not experience significant returns. As necessary, a provision is recorded for estimated sales returns and allowances and is deducted from gross product revenue to arrive at net product revenue in the period the related revenue is recorded. These estimates are based on historical sales returns and allowances and other known factors. Actual returns and claims in any future period are inherently uncertain and thus may differ from these estimates. If actual or expected future returns and claims are significantly greater or lower than the reserves established, a reduction or increase to revenue will be recorded in the period in which such a determination is made. All non-income government-assessed taxes (sales and use taxes) collected from the Company’s customers and remitted to governmental agencies are recorded in accrued expenses until they are remitted to the government agency. The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company’s contracts. Contract liabilities The Company recognizes a contract liability when a customer pays for goods or services for which the Company has not yet transferred control. The balances of the Company’s contract liabilities are as follows: September 30, December 31, 2024 2023 (in thousands) Total contract liabilities - extended service contracts $ 1,147 $ 920 Less: long-term portion 230 302 Contract liabilities – current $ 917 $ 618 Contract liabilities are included within other current liabilities and other long-term liabilities in the accompanying unaudited condensed consolidated balance sheets. Revenue recognized during each of the three months ended September 30, 2024 and 2023 that was included in the contract liability balance as of June 30, 2024 and 2023 was immaterial. Revenue recognized during the nine months ended September 30, 2024 and 2023 that was included in the contract liability balance as of December 31, 2023 and 2022 was $ 0.5 million and $ 0.3 million , respectively. Disaggregation of revenue The Company disaggregates revenue from contracts with customers by the timing of when goods and services are transferred, which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected. The following table provides information regarding disaggregated revenues and the timing of when goods and services are transferred: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Product revenue recognized at a point in time $ 7,662 $ 7,934 $ 22,333 $ 25,075 Service revenue recognized over time 374 229 1,064 529 Total revenue $ 8,036 $ 8,163 $ 23,397 $ 25,604 No individual customer accounted for more than 10% of sales for the three and nine months ended September 30 , 2024 and 2023. Allowance for credit losses At each reporting period the Company recognizes or revises its estimate of expected credit losses for financial assets and other assets within the scope of the current expected credit losses (“CECL”) model under ASC 326, which include its trade receivables. The Company records reserves for accounts receivables as they age, as adjusted based on factors including changes in credit terms, recent collection trend and existence of payment plans. As of September 30, 2024, the allowance for credit losses was approximately $ 0.3 million. Warranty Reserve The Company provides a standard warranty on its GentleWave Systems for a specified period of time. For the nine months ended September 30, 2024 and 2023, GentleWave Systems sold were covered by the warranty for a period of up to two years from the date of sale. Estimated warranty costs are recorded as a liability at the time of delivery with a corresponding provision to cost of sales. Warranty accruals are estimated based on the current product costs, the Company’s historical experience, management’s expectations of future conditions and standard maintenance schedules. The Company evaluates this reserve on a regular basis and makes adjustments as necessary. The following table provides a reconciliation of the change in estimated warranty liabilities for the nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Balance at beginning of period $ 754 $ 1,579 $ 1,269 $ 1,930 Provision for warranties issued 177 170 620 570 Changes in estimate of pre-existing warranty — — ( 112 ) — Warranty costs incurred ( 316 ) ( 384 ) ( 1,162 ) ( 1,135 ) Balance at end of period $ 615 $ 1,365 $ 615 $ 1,365 Current portion $ 574 $ 1,228 Non-current portion 41 137 Total $ 615 $ 1,365 The warranty liabilities, current and non-current, are included in other current liabilities and other liabilities, respectively, on the unaudited condensed consolidated balance sheets. Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASU”). ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s unaudited condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which expands on segment reporting requirements primarily through enhanced disclosures surrounding significant segment expenses. The ASU expands on existing segment reporting requirements to require that a public entity, including entities with a single reportable segment, disclose, on an annual and interim basis, significant segment expenses that are regularly provided to an entity's CODM, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is evaluating the impact of this ASU on its Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments require disclosure of specific categories in the rate reconciliation and provides additional information for reconciling items that meet a quantitative threshold and further disaggregation of income taxes paid for individually significant jurisdictions. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the adoption to have a material impact on its Consolidated Financial Statements. In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU intends to improve income statement expense disclosure requirements, primarily through enhanced disclosure about certain costs and expenses included in income statement expense captions. The amendments are effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the impact of this ASU on its Consolidated Financial Statements.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	3. Discontinued Operations On March 1, 2024, the Company entered into an Asset Purchase Agreement by and among TDO, Valsoft Corporation Inc., a Quebec corporation, and Aspire USA LLC, a Delaware limited liability company and affiliate of Valsoft (collectively “Valsoft”), pursuant to which TDO agreed to sell to Valsoft substantially all the assets and liabilities relating to the Company’s software segment. As consideration for the transaction, Valsoft agreed to pay TDO approximately $ 16.0 million, with $ 15.0 million paid on March 1, 2024 and $ 1.0 million due approximately 12 months post-closing. In connection with the transaction, Valsoft agreed to make offers of employment to certain employees of the Business on terms that are comparable to those currently in effect for such employees. The Asset Purchase Agreement contains certain representations, warranties and covenants of each of TDO and Valsoft. Each of TDO and the Valsoft has agreed to indemnify the other for certain losses arising out of breaches of representations and covenants and for certain losses arising out of retained liabilities or assumed liabilities relating to the TDO business, as applicable, subject to customary limitations. The divestiture met the criteria to be accounted for as a discontinued operation as of March 31, 2024. Accordingly, the operating results of the discontinued operations for the three and nine months ended September 30, 2024 and 2023, respectively, are presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss within income from discontinued operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) (in thousands) Revenue $ — $ 2,243 $ 1,478 $ 6,569 Cost of sales — 681 511 2,056 Gross profit — 1,562 967 4,513 Operating expenses: General and administrative — 398 524 1,254 Selling and marketing — 197 162 535 Research and development — 498 476 1,599 Income (loss) from discontinued operations, net of tax — 469 ( 195 ) 1,125 Other income — — — 22 Gain on sale of discontinued operations, net of tax — — 5,703 — Net income from discontinued operations $ — $ 469 $ 5,508 $ 1,147 Software is licensed via delivery to the customer or via a service arrangement under which cloud-based access is provided on a subscription basis (software-as-a-service). When a fixed up-front license fee is received in exchange for the delivery of software, revenue is recognized at the point in time when the delivery of the software has occurred. When software is licensed on a subscription basis, revenue is recognized over the respective license period. The following table presented assets and liabilities of discontinued operations as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 (in thousands) Current assets: $ 1,000 $ 656 Non-current assets: Intangible assets, net — 661 Goodwill — 8,454 Other — 482 Total assets of discontinued operations $ 1,000 $ 10,253 Current liabilities: Accounts payable $ — $ 34 Accrued expenses — 194 Accrued compensation — 345 Operating lease liabilities — 127 Total liabilities of discontinued operations $ — $ 700 During the three months ended September 30, 2024, no depreciation and amortization of long-lived assets was recorded in the discontinued operations. During the nine months ended September 30, 2024, $ 60 thousand expenses of depreciation and amortization of long-lived assets was recorded in the discontinued operations. During the three and nine months ended September 30, 2023, $ 0.1 million and $ 0.4 million expenses of depreciation and amortization of long-lived assets was recorded in the discontinued operations. For each of the three and nine months ended September 30, 2024 and 2023, no capital expenditure was recorded in the discontinued operations. See Note 7 “Stock based Compensation.” for stock based compensation expense recorded in the discontinued operations for each of the three and nine months ended September 30 , 2024 and 2023.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	4. Balance Sheet Components Inventory Inventory consisted of the following: September 30, December 31, 2024 2023 (in thousands) Raw materials $ 5,693 $ 6,450 Work in process 230 278 Finished goods 5,564 4,346 Total inventory $ 11,487 $ 11,074 The balance of the reserve of excess and obsolete inventory was $ 1.0 million and $ 0.8 million as of September 30, 2024 and December 31, 2023, respectively. During the three and nine months ended September 30, 2024, the Company recorded a reserve for excess and obsolete inventory of $ 0.1 million and $ 0.3 million, respectively, related to phasing out the legacy GentleWave Console (“Gen3”) and legacy molar and anterior pre-molar procedure instruments. During the nine months ended September 30, 2023, the Company recorded a reserve for excess and obsolete inventory of $ 1.7 million related to reduced sales volumes of legacy Gen3, and a charge of $ 1.2 million related to phasing out the legacy molar and anterior pre-molar procedure instruments as the Company moved to the CleanFlow procedure instruments, of which $ 0.6 million was due to excess and obsolete inventory.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	5. Fair Value of Financial Instruments The Company applies fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. The Company’s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable, operating lease liabilities, warrant liabilities and a term loan. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value measurement assumes that the transaction to sell the asset or transfer the liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 – Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities the Company has the ability to access. Level 2 – Inputs (other than quoted prices included within Level 1) that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3 – Unobservable inputs that are significant to the fair value measurement and reflect the reporting entity’s use of significant management judgment and assumptions when there is little or no market data. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the periods presented. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and certain accrued expenses approximate fair value due to the short-term nature of these items. Accordingly, the Company estimates that the recorded amounts approximate fair market value. The following table provides the assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such value at September 30, 2024 and December 31, 2023: September 30, 2024 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Cash equivalents: Money market funds $ 11,789 $ 11,789 $ — $ — U.S. treasury securities 750 750 — — Total cash equivalents at fair value 12,539 12,539 — — Short-term investments: U.S. treasury securities 1,487 1,487 — — Commercial paper and corporate bonds 2,701 — 2,701 — Total short-term investments at fair value 4,188 1,487 2,701 — Total assets at fair value $ 16,727 $ 14,026 $ 2,701 $ — September 30, 2024 Fair Cost Amounts Recognized in Accumulated Other Comprehensive Loss Unrealized Gains Unrealized Losses (in thousands) Available-for-sale securities: U.S. treasury securities $ 1,487 $ 1,485 $ 2 $ — Commercial paper and corporate bonds 2,701 2,700 1 — Total available-for-sale securities at fair value $ 4,188 $ 4,185 $ 3 $ — December 31, 2023 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Cash equivalents: Money market funds $ 10,761 $ 10,761 $ — $ — Corporate Bonds 1,827 — 1,827 — Total cash equivalents at fair value 12,588 10,761 1,827 — Short-term investments: U.S. treasury securities 14,826 14,826 — — Commercial paper and corporate bonds 13,204 — 13,204 — U.S. government agency bonds 4,743 — 4,743 — Total short-term investments at fair value 32,773 14,826 17,947 — Total assets at fair value $ 45,361 $ 25,587 $ 19,774 $ — Money market funds and U.S. Treasury securities are highly liquid investments and are actively traded. The pricing information on these investment instruments is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. Commercial paper, U.S. government agency bonds and corporate bonds are measured at fair value using Level 2 inputs. The Company reviews trading activity and pricing for these investments as of each measurement date. When sufficient quoted pricing for identical securities is not available, the Company uses market pricing and other observable market inputs for similar securities obtained from third party data providers. These inputs represent quoted prices for similar assets in active markets or these inputs have been derived from observable market data. This approach results in the classification of these securities as Level 2 of the fair value hierarchy.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders' Equity	6. Stockholders’ Equity Warrants Warrants issued to Perceptive Credit Holdings III, LP (“Perceptive”) and certain of its affiliates and outstanding at December 31, 2023 included 95 warrants with exercise price of $ 2,190 per share and 1,518 warrants with exercise price of $ 2,400 per share. Warrants issued and outstanding at September 30, 2024 includes 1,518 warrants with exercise price of $ 2,400 per share. These warrants expire between June 2027 and August 2031 . The Company issued pre-funded warrants to certain institutional investors and accredited investors in a previous private placement. As of September 30, 2024, approximately 157.2 thousand shares have been issued pursuant to the exercise of pre-funded warrants and 59.3 thousand shares underlying the pre-funded warrants remain outstanding. The pre-funded warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time of issuance. The pre-funded warrants are included in the calculation of basic and diluted loss per share.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation	7. Stock Based Compensation Stock-based Compensation Expenses The following tables present the Company’s stock-based compensation for stock-settled awards by type (i.e., stock options and restricted stock units (“RSUs”) granted under the Company’s incentive plans, and rights to purchase shares of common stock issued under the Company’s Employee Stock Purchase Plan (“ESPP”) and financial statement lines included in the accompanying unaudited condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30: Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 (in thousands) Options $ 233 $ 645 $ 880 $ 2,233 RSUs 397 1,094 3,343 3,389 ESPP — 45 — 163 Total stock-based compensation expense $ 630 $ 1,784 $ 4,223 $ 5,785 Three months ended September 30, 2024 2023 Continuing operations Discontinued operations Total Continuing operations Discontinued operations Total (in thousands) Cost of sales $ 14 $ — $ 14 $ 44 $ 10 $ 54 Selling and marketing 47 — 47 550 6 556 General and administrative 539 — 539 1,010 19 1,029 Research and development 30 — 30 136 9 145 Total stock-based compensation expense $ 630 $ — $ 630 $ 1,740 $ 44 $ 1,784 Nine months ended September 30, 2024 2023 Continuing operations Discontinued operations Total Continuing operations Discontinued operations Total (in thousands) Cost of sales $ 324 $ 79 $ 403 $ 262 $ 31 $ 293 Selling and marketing 838 59 897 1,698 18 1,716 General and administrative 2,141 140 2,281 3,156 55 3,211 Research and development 551 91 642 538 27 565 Total stock-based compensation expense $ 3,854 $ 369 $ 4,223 $ 5,654 $ 131 $ 5,785 During the nine months ended September 30, 2024, the Company accelerated vesting of outstanding RSUs granted to certain non-executive employees in the continuing operations and recognized $ 1.6 million unamortized compensation expenses associated with these RSUs, with approximately $ 0.3 million expenses recorded in cost of sales, $ 0.6 million in selling and marketing, $ 0.2 million in general and administrative and $ 0.4 million in research and development. During the nine months ended September 30, 2024, the Company accelerated vesting of outstanding RSUs granted to certain non-executive employees in the discontinued operations and recognized $ 0.3 million unamortized compensation expenses associated with these RSUs, as presented in the table above. Compensation cost related to unvested stock options and RSUs will generally be amortized on a straight-line basis over the remaining average service period. T he following table presents the unamortized compensation cost and weighted average service period of all unvested outstanding awards as of September 30, 2024. Unamortized Compensation Costs Weighted Average Service Period (in thousands) (years) Options $ 660 0.75 RSUs 2,978 3.28 Total unamortized compensation cost $ 3,638 Plan Activities T he following table summarizes stock option activity under the Company’s incentive plans: Number Weighted Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Options outstanding, December 31, 2023 11,786 $ 571.27 6.3 $ — Forfeited/Expired ( 3,670 ) Options outstanding, September 30, 2024 8,116 $ 592.24 5.2 $ — Options vested and exercisable, September 30, 2024 7,600 $ 559.60 5.1 $ — There were no options granted during the nine months ended September 30, 2024. The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2023 wa s $ 0.83 . The following table summarizes the non-vested stock options that were outstanding as of September 30, 2024 and December 31, 2023: Number of Shares Weighted Non-vested Options, December 31, 2023 2,217 $ 1,045.01 Non-vested Options, September 30, 2024 505 $ 1,736.21 The total fair value of shares vested during the nine months ended September 30, 2024 and 2023 was $ 2.8 million and $ 2.1 million , respectively. Certain stock option grants under the 2017 Stock Incentive Plan (the “2017 Plan”) allow the recipient to exercise the options prior to the options becoming fully vested. Under the 2017 Plan, the Company retains the right to repurchase shares of its common shares that have been issued upon early exercise of options at the original issue price. During the nine months ended September 30, 2024, the Company did not repurchase any shares. There was not a material number of shares of common stock subject to repurchase as of September 30, 2024. Cash received for the early exercise of unvested stock options is initially recorded as a liability and released to equity over the vesting period. There were no early exercised stock options during the nine months ended September 30, 2024 and 2023. T he following table summarizes RSU activity under the Company’s incentive plans: Number Weighted RSUs outstanding, December 31, 2023 16,593 $ 517.03 Granted 29,194 $ 7.98 Vested ( 6,245 ) $ 570.64 Forfeited ( 4,120 ) $ 502.49 RSUs outstanding, September 30, 2024 35,422 $ 87.71 During the nine months ended September 30, 2024, vested RSUs included a total of 2,947 aforementioned the accelerated vesting of outstanding RSUs to certain employees.

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Leases	8. Leases The Company leases office space under operating leases with expirations ranging from March 2025 to March 2028, some of which include rent escalations or an option to extend the lease for up to three years per renewal. The exercise of lease renewal options is at the sole discretion of the Company. During the nine months ended September 30, 2024 , the Company has not entered into any new leases that would entitle the Company to significant rights or create additional obligations. The Company determines whether a contract is or contains a lease at the inception of the contract. A contract will be deemed to be or contain a lease if the contract conveys the right to control and direct the use of identified property, plant, or equipment for a period of time in exchange for consideration. The Company generally must also have the right to obtain substantially all of the economic benefits from the use of the property, plant, and equipment. The Company has elected the practical expedient to not separate its lease component from non-lease component for its real estate leases. The Company has elected the practical expedient not to apply the lease recognition requirements to short-term leases with an initial term of 12 months or less. The Company uses either its incremental borrowing rate or the implicit rate in the lease agreement as the basis to calculate the present value of future lease payments at lease commencement. The incremental borrowing rate represents the rate the Company would have to pay to borrow funds on a collateralized basis over a similar term and in a similar economic environment. Future minimum lease payments under these leases are as follows: Lease Amounts (in thousands) 2024 (remaining three months) $ 202 2025 991 2026 938 2027 480 2028 122 Total future minimum lease payments 2,733 Less: Imputed Interest ( 279 ) Present value of operating lease liabilities $ 2,454 Less: Current portion 884 Long-term operating lease liabilities $ 1,570 Weighted average remaining lease term in years 2.84 Weighted average discount rate 8.10 % Variable operating lease expenses consist primarily of real estate taxes and insurance. The components of lease expense and related cash flows were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Rent expense $ 297 $ 373 $ 969 $ 1,140 Variable lease costs 48 17 49 81 Total $ 345 $ 390 $ 1,018 $ 1,221 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Cost of sales $ 59 $ 67 $ 189 $ 205 General and administrative 286 323 829 1,016 Total $ 345 $ 390 $ 1,018 $ 1,221 Cash paid for operating leases $ 310 $ 382 $ 1,008 $ 1,140

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business, including without limitation, actions with respect to intellectual property, employment, regulatory, product liability and contractual matters. For example, on January 22, 2024, a former employee whose position was eliminated as part of the Company’s reduction-in-force, filed a complaint against the Company, alleging various violations of California wage and hour laws, including unpaid meal and rest period premiums. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible issues based on the developments in these proceedings or matters. A liability is recorded in the accompanying unaudited condensed consolidated financial statements if it is determined that it is probable that a loss will be incurred, and that the amount (or range) of the loss can be reasonably estimated. The Company’s management currently does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

Term Loan

Term Loan	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Term Loan	10. Term Loan Perceptive loan On January 13, 2023, the Company entered into Amendment No. 2 (the “Second Amendment”) to the Amended and Restated Credit Agreement and Guaranty by and among the Company, the Subsidiary Guarantors party thereto, the Lenders party thereto and Perceptive (the “Amended Perceptive Loan Agreement”) to replace the existing benchmark rate from the one-month LIBOR with a one-month Secured Overnight Financing Rate (“SOFR”). All other terms remain unchanged on the original agreement. For the nine months ended September 30, 2024 and 2023 , the interest rate for amounts borrowed under the Amended Perceptive Loan Agreement was the greater of the one-month SOFR and 2.00 % plus the applicable margin of 9.25 %. On March 1, 2024, the Company entered into Amendment No. 3 (the “Third Amendment”) to the Amended Perceptive Loan Agreement. Pursuant to the Third Amendment, the Company made a one-time $ 15.0 million principal repayment on March 1, 2024, and made an amortization payment of $ 1.8 million on the outstanding principal on March 31, 2024 and agreed to make monthly amortization payments on the outstanding principal each in the amount of $ 0.9 million on each payment date commencing on April 30, 2024 . Accordingly, $ 1.0 million of the unamortized debt issuance costs were expensed in connection with the Third Amendment. For the nine months ended September 30, 2024 and 2023, the effective interest rate of the Amended Perceptive L oan, was 21.10 % and 17.39 %, respectively. As of September 30, 2024 and December 31, 2023, the fair value of the Amended Perceptive Loan approxim ates its carrying amount. Pursuant to the Third Amendment, future principal repayments and the net carrying value of the Perceptive Loan as of September 30, 2024, are as follows: Principal (in thousands) Remaining 3 months of 2024 $ 2,700 2025 10,800 2026 4,300 Total principal payment 17,800 Debt discounts ( 916 ) Net carrying value $ 16,884 The Company is permitted to make voluntary prepayments, subject to a scaled prepayment premium that ranges from 7.0 % to 1.0 % of the aggregate principal amount outstanding on such prepayment date for prepayments made after August 23, 2022 and before August 23, 2025. No prepayment premium is required for payments made after August 23, 2025. The Amended Perceptive Loan Agreement contains events of default, including, without limitation, upon: (i) failure to make a payment pursuant to the terms of the agreement; (ii) violation of certain covenants; (iii) payment or other defaults on other indebtedness; (iv) material adverse change in the business or change in control; (v) insolvency; (vi) significant judgments; (vii) incorrectness of representations and warranties; (viii) regulatory matters; and (ix) failure by us to maintain a valid and perfected lien on the collateral securing the borrowing. Based on the Amended Perceptive Loan Agreement, the Company has granted a security interest in substantially all of its assets. The Amended Perceptive Loan Agreement includes financial covenants that require the Company to (i) maintain, at all times, a minimum aggregate balance of $ 3.0 million in cash in one or more controlled accounts, and (ii) pursuant to the Third Amendment, satisfy certain minimum revenue thresholds, measured for the consecutive 12-month periods ending on each calendar quarter-end until September 30, 2026 as follows: For 12-month Period Ending Revenue (in thousands) September 30, 2024 $ 33,000 December 31, 2024 $ 31,500 March 31, 2025 $ 31,000 June 30, 2025 $ 33,000 September 30, 2025 $ 35,935 December 31, 2025 $ 40,160 March 31, 2026 $ 44,950 June 30, 2026 $ 51,500 Pursuant to the Third Amendment, the lender also waived the covenant requiring the absence of any “going concern” or like qualification or exception or any qualification or exception as to the scope of the audit, solely with respect to the fiscal year ending on December 31, 2023 . Failure to satisfy any covenants would constitute an event of default under the Amended Perceptive Loan Agreement. In the event of an event of default, the lender may terminate its commitments and declare all amounts outstanding under the Amended Perceptive Loan Agreement immediately due and payable, together with accrued interest and all fees and other obligations. The amount of such repayment will include payment of any prepayment premium applicable due to the time of such payment. In addition, upon the occurrence and during the continuance of any event of default, the applicable margin will increase by 3.00 % per annum to 12.25 %. Total revenue generated from continuing and discontinued operations for the 12-months period ended September 30, 2024 was $ 36.5 million , and the cash and cash equivalents and short term investment balance was $ 17.3 million as of September 30, 2024. As such, the Company was in compliance with all financial covenants and conditions under the Amended Perceptive Loan Agreement as of September 30 , 2024.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The Company maintains a full valuation allowance against its net deferred tax assets as of September 30, 2024 based on the current assessment that it is not more likely than not these future benefits will be realized before expiration. No material income tax expense or benefit has been recorded given the valuation allowance position and projected taxable losses in the jurisdictions where the Company files income tax returns. The Company has not experienced any significant increases or decreases to its unrecognized tax benefits since December 31, 2023 and does not expect any within the next 12 months. The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. Utilization of the net operating loss carryforwards may be subject to substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change,” as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. The Company has not completed an analysis regarding the limitation of net operating loss and R&D credit carryforwards as of September 30, 2024. The Company is subject to U.S. federal and various states income taxes. The federal returns for tax y ears 2021 through 2023 remain open to examination and the state returns remain subject to examination for tax years 2020 through 2023 . Carryforward attributes that were generated in years where the statute of limitations is closed may still be adjusted upon examination by the Internal Revenue Service or other respective tax authorities. All other state jurisdictions remain open to examination. In October 2024, the Company was notified that it was selected for examination by the Internal Revenue Service for its federal income tax return for the fiscal year 2022 period. The Company does not expect the results of the audit to have a material impact on its financial results.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment Information	12. Segment Information The Company previously operated and reported its results in two business segments, Product and Software. Software segment assets included goodwill and intangible assets, which were derecognized in connection with the divestiture of the software business on March 1, 2024. Following the divestiture, there were no substantial assets or operations of the software segment. The software segment was reported as discontinued operations as of September 30, 2024, and is presented as such for all periods in this report. For more information, see Note 3 “Discontinued Operations.”

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands, except shares and per share data) (in thousands, except shares and per share data) Numerator: Loss from continuing operations, net of tax $ ( 7,536 ) $ ( 17,449 ) $ ( 27,171 ) $ ( 51,188 ) Income from discontinued operations, net of tax — 469 5,508 1,147 Net loss $ ( 7,536 ) $ ( 16,980 ) $ ( 21,663 ) $ ( 50,041 ) Denominator: Weighted-average shares outstanding – basic and diluted 477,857 471,427 475,188 469,934 Net loss per share – basic and diluted $ ( 15.77 ) $ ( 36.02 ) $ ( 45.59 ) $ ( 106.49 ) For the three months and the nine months ended September 30, 2024 and 2023, the Company recorded a net loss, and all shares subject to outstanding equity awards were excluded from the calculation of diluted shares for those periods because their impact would have been anti-dilutive.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Event	1 4. Subsequent Event Reverse Stock Split On October 16, 2024, the Company filed an amendment to our Amended and Restated Certificate of Incorporation to implement a 1-for-200 reverse stock split of its issued and outstanding common stock, effective as of October 18, 2024. The reverse stock split was announced by FINRA on its OTC Daily List on November 7,2024 and took effect at the open of trading on November 8, 2024 on the OTCQX. The reverse stock split correspondingly adjusted the per share exercise price of all outstanding options and all shares underlying any of the Company’s outstanding warrants by reducing the conversion ratio for each outstanding warrant and increasing the applicable exercise price or conversion price in accordance with the terms of each outstanding warrant and based on the reverse stock split ratio. No fractional shares were issued in connection with the reverse stock split. The number of shares of common stock authorized under the Company’s Amended and Restated Certificate of Incorporation is unchanged at 500,000,000 shares. The accompanying interim unaudited condensed financial statements reflect the 1-for-200 reverse split of the Company’s common stock. All share and per share information data herein that relates to common stock prior to the effective date has been retroactively restated to reflect the reverse stock split. Biolase Assets Auction On September 30, 2024, the Company entered into an Asset Purchase Agreement (the “Biolase Asset Purchase Agreement”) with Biolase, Inc., a Delaware corporation (“Biolase”), BL Acquisition Corp., a Delaware corporation (“BL Acquisition”), BL Acquisition II, Inc., a Delaware corporation (“BL Acquisition II”), and Model Dental Office, LLC, a Delaware limited liability company (“MDO” and together with Biolase, BL Acquisition and BL Acquisition II, each a “Seller” and collectively, the “Sellers”), pursuant to which, subject to the terms and conditions set forth in the Biolase Asset Purchase Agreement, the Company was designated as the “stalking horse” bidder in connection with a sale of certain assets of Biolase under Section 363 of Title 11 of the United States Code for a total purchase price of (i) $ 14 million in cash subject to a downward working capital adjustment, (ii) the assumption of liabilities and (iii) the value of the Delaware Litigation (as defined in the Biolase Asset Purchase Agreement) (the “Purchase Price”). The Sellers conducted a bankruptcy auction on November 4, 2024. Based on the result of that auction, the Company was not the winning bidder. Accordingly, the Company does not expect to proceed with the transaction described in the Biolase Asset Purchase Agreement except in the unlikely event the winning bidder fails to close. Subject to final Bankruptcy Court approval, the Biolase Asset Purchase Agreement will be terminated upon the sale of the Biolase assets to the prevailing bidder, and the Sellers will be required to pay the Company a break-up fee equal to 3 % of the Purchase Price plus a capped expense reimbursement of up to approximately $ 0.6 million. Additionally, 10 % of the Purchase Price that was placed into escrow at the time of signing, will be returned to the Company upon the termination of the Biolase Asset Purchase Agreement. For the three and nine months ended September 30, 2024, the Company incurred $ 0.9 million of transaction and financing expenses related to the Biolase acquisition, which were recorded in the general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.

Summary Accounting Policies a_2

Summary Accounting Policies and Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make informed estimates, judgements and assumptions that affect the reported amounts in the unaudited condensed consolidated financial statements and disclosures in the accompanying notes, including estimates of probable losses and expenses, as of the date of the accompanying unaudited condensed consolidated financial statements. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of these unaudited condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying unaudited condensed consolidated financial statements under different assumptions or conditions.
Inventory	Inventory Inventory consists of finished products, work-in-process and raw materials and is valued at the lower of cost or net realizable value. Cost may include materials, labor and manufacturing overhead. Cost is determined by the first in, first out inventory method. The carrying value of inventory is reviewed for potential impairment whenever indicators suggest that the cost of inventory exceeds the carrying value and management adjusts the inventory to its net realizable value. The Company also periodically evaluates inventory for estimated losses from excess quantities and obsolescence and writes down the cost of inventory to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs of completion and disposal.
Revenue Recognition	Revenue Recognition Contracts with Customers The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five core principles to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. Revenue recorded from continuing operations is generated from sales of the GentleWave Console and related PIs and accessories and services on its GentleWave Console. The Company’s products are sold primarily in the United States and Canada directly to customers through its field sales force. Performance Obligations The Company’s performance obligations from continuing operations primarily arise from the manufacture and delivery of the GentleWave System, related PIs and accessories, and to a lesser extent, performance of service contracts on its GentleWave Consoles. Payment terms are typically on open credit terms consistent with industry practice and do not have significant financing components. Consideration may be variable based on volume. The Company considers the individual deliverables in its product offering as separate performance obligations and assesses whether each promised good or service is distinct. The total contract transaction price is determined based on the consideration expected to be received, based on the stated value in contractual arrangements or the estimated cash to be collected in no-contracted arrangements, and is allocated to the identified performance obligations based upon the relative standalone selling prices of the performance obligations. The stand-alone selling price is based on an observable price offered to other comparable customers. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary. The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur. The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company estimates related variable consideration at the point of sale, including discounts, product returns, refunds, and other similar obligations. Revenue is recognized over time when the customer simultaneously receives and consumes the benefits provided by the Company’s performance. Revenue is recognized at a point in time if the criteria for recognizing revenue over time are not met, and the Company has transferred control of the goods to the customer. Product revenue is recognized at a point in time when the Company has transferred control to the customer, which is generally when title of the goods transfers to the customer. Sales of extended service contracts are recorded as deferred revenue until such time as the standard warranty expires, which is generally up to two years from the date of sale. Service contract revenue is recognized on a straight-line basis over time consistent with the life of the related service contract in proportion to the costs incurred in fulfilling performance obligations under the service contract. The Company generally does not experience significant returns. As necessary, a provision is recorded for estimated sales returns and allowances and is deducted from gross product revenue to arrive at net product revenue in the period the related revenue is recorded. These estimates are based on historical sales returns and allowances and other known factors. Actual returns and claims in any future period are inherently uncertain and thus may differ from these estimates. If actual or expected future returns and claims are significantly greater or lower than the reserves established, a reduction or increase to revenue will be recorded in the period in which such a determination is made. All non-income government-assessed taxes (sales and use taxes) collected from the Company’s customers and remitted to governmental agencies are recorded in accrued expenses until they are remitted to the government agency. The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company’s contracts. Contract liabilities The Company recognizes a contract liability when a customer pays for goods or services for which the Company has not yet transferred control. The balances of the Company’s contract liabilities are as follows: September 30, December 31, 2024 2023 (in thousands) Total contract liabilities - extended service contracts $ 1,147 $ 920 Less: long-term portion 230 302 Contract liabilities – current $ 917 $ 618 Contract liabilities are included within other current liabilities and other long-term liabilities in the accompanying unaudited condensed consolidated balance sheets. Revenue recognized during each of the three months ended September 30, 2024 and 2023 that was included in the contract liability balance as of June 30, 2024 and 2023 was immaterial. Revenue recognized during the nine months ended September 30, 2024 and 2023 that was included in the contract liability balance as of December 31, 2023 and 2022 was $ 0.5 million and $ 0.3 million , respectively. Disaggregation of revenue The Company disaggregates revenue from contracts with customers by the timing of when goods and services are transferred, which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected. The following table provides information regarding disaggregated revenues and the timing of when goods and services are transferred: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Product revenue recognized at a point in time $ 7,662 $ 7,934 $ 22,333 $ 25,075 Service revenue recognized over time 374 229 1,064 529 Total revenue $ 8,036 $ 8,163 $ 23,397 $ 25,604 No individual customer accounted for more than 10% of sales for the three and nine months ended September 30 , 2024 and 2023.
Allowance for credit losses	Allowance for credit losses At each reporting period the Company recognizes or revises its estimate of expected credit losses for financial assets and other assets within the scope of the current expected credit losses (“CECL”) model under ASC 326, which include its trade receivables. The Company records reserves for accounts receivables as they age, as adjusted based on factors including changes in credit terms, recent collection trend and existence of payment plans. As of September 30, 2024, the allowance for credit losses was approximately $ 0.3 million.
Warranty Reserve	Warranty Reserve The Company provides a standard warranty on its GentleWave Systems for a specified period of time. For the nine months ended September 30, 2024 and 2023, GentleWave Systems sold were covered by the warranty for a period of up to two years from the date of sale. Estimated warranty costs are recorded as a liability at the time of delivery with a corresponding provision to cost of sales. Warranty accruals are estimated based on the current product costs, the Company’s historical experience, management’s expectations of future conditions and standard maintenance schedules. The Company evaluates this reserve on a regular basis and makes adjustments as necessary. The following table provides a reconciliation of the change in estimated warranty liabilities for the nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Balance at beginning of period $ 754 $ 1,579 $ 1,269 $ 1,930 Provision for warranties issued 177 170 620 570 Changes in estimate of pre-existing warranty — — ( 112 ) — Warranty costs incurred ( 316 ) ( 384 ) ( 1,162 ) ( 1,135 ) Balance at end of period $ 615 $ 1,365 $ 615 $ 1,365 Current portion $ 574 $ 1,228 Non-current portion 41 137 Total $ 615 $ 1,365 The warranty liabilities, current and non-current, are included in other current liabilities and other liabilities, respectively, on the unaudited condensed consolidated balance sheets.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASU”). ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s unaudited condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which expands on segment reporting requirements primarily through enhanced disclosures surrounding significant segment expenses. The ASU expands on existing segment reporting requirements to require that a public entity, including entities with a single reportable segment, disclose, on an annual and interim basis, significant segment expenses that are regularly provided to an entity's CODM, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is evaluating the impact of this ASU on its Consolidated Financial Statements. In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments require disclosure of specific categories in the rate reconciliation and provides additional information for reconciling items that meet a quantitative threshold and further disaggregation of income taxes paid for individually significant jurisdictions. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not expect the adoption to have a material impact on its Consolidated Financial Statements. In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU intends to improve income statement expense disclosure requirements, primarily through enhanced disclosure about certain costs and expenses included in income statement expense captions. The amendments are effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the impact of this ASU on its Consolidated Financial Statements.

Summary Accounting Policies a_3

Summary Accounting Policies and Recent Accounting Pronouncements (Tables)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Balances of Contract Liabilities	The Company recognizes a contract liability when a customer pays for goods or services for which the Company has not yet transferred control. The balances of the Company’s contract liabilities are as follows: September 30, December 31, 2024 2023 (in thousands) Total contract liabilities - extended service contracts $ 1,147 $ 920 Less: long-term portion 230 302 Contract liabilities – current $ 917 $ 618
Schedule of Revenues Disaggregated by Segment and Timing of Goods and Services Transferred	The following table provides information regarding disaggregated revenues and the timing of when goods and services are transferred: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Product revenue recognized at a point in time $ 7,662 $ 7,934 $ 22,333 $ 25,075 Service revenue recognized over time 374 229 1,064 529 Total revenue $ 8,036 $ 8,163 $ 23,397 $ 25,604 No individual customer accounted for more than 10% of sales for the three and nine months ended September 30 , 2024 and 2023.
Schedule of Reconciliation of Change in Estimated Warranty Liabilities	The following table provides a reconciliation of the change in estimated warranty liabilities for the nine months ended September 30, 2024 and 2023: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Balance at beginning of period $ 754 $ 1,579 $ 1,269 $ 1,930 Provision for warranties issued 177 170 620 570 Changes in estimate of pre-existing warranty — — ( 112 ) — Warranty costs incurred ( 316 ) ( 384 ) ( 1,162 ) ( 1,135 ) Balance at end of period $ 615 $ 1,365 $ 615 $ 1,365 Current portion $ 574 $ 1,228 Non-current portion 41 137 Total $ 615 $ 1,365

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Summary Of Operations and Comprehensive Loss And Balance Sheet Of Discontinued Operations	The divestiture met the criteria to be accounted for as a discontinued operation as of March 31, 2024. Accordingly, the operating results of the discontinued operations for the three and nine months ended September 30, 2024 and 2023, respectively, are presented in the Condensed Consolidated Statements of Operations and Comprehensive Loss within income from discontinued operations as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) (in thousands) Revenue $ — $ 2,243 $ 1,478 $ 6,569 Cost of sales — 681 511 2,056 Gross profit — 1,562 967 4,513 Operating expenses: General and administrative — 398 524 1,254 Selling and marketing — 197 162 535 Research and development — 498 476 1,599 Income (loss) from discontinued operations, net of tax — 469 ( 195 ) 1,125 Other income — — — 22 Gain on sale of discontinued operations, net of tax — — 5,703 — Net income from discontinued operations $ — $ 469 $ 5,508 $ 1,147 The following table presented assets and liabilities of discontinued operations as of September 30, 2024 and December 31, 2023: September 30, 2024 December 31, 2023 (in thousands) Current assets: $ 1,000 $ 656 Non-current assets: Intangible assets, net — 661 Goodwill — 8,454 Other — 482 Total assets of discontinued operations $ 1,000 $ 10,253 Current liabilities: Accounts payable $ — $ 34 Accrued expenses — 194 Accrued compensation — 345 Operating lease liabilities — 127 Total liabilities of discontinued operations $ — $ 700

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Schedule of Inventory	Inventory consisted of the following: September 30, December 31, 2024 2023 (in thousands) Raw materials $ 5,693 $ 6,450 Work in process 230 278 Finished goods 5,564 4,346 Total inventory $ 11,487 $ 11,074

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table provides the assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such value at September 30, 2024 and December 31, 2023: September 30, 2024 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Cash equivalents: Money market funds $ 11,789 $ 11,789 $ — $ — U.S. treasury securities 750 750 — — Total cash equivalents at fair value 12,539 12,539 — — Short-term investments: U.S. treasury securities 1,487 1,487 — — Commercial paper and corporate bonds 2,701 — 2,701 — Total short-term investments at fair value 4,188 1,487 2,701 — Total assets at fair value $ 16,727 $ 14,026 $ 2,701 $ — December 31, 2023 Fair Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (in thousands) Assets: Cash equivalents: Money market funds $ 10,761 $ 10,761 $ — $ — Corporate Bonds 1,827 — 1,827 — Total cash equivalents at fair value 12,588 10,761 1,827 — Short-term investments: U.S. treasury securities 14,826 14,826 — — Commercial paper and corporate bonds 13,204 — 13,204 — U.S. government agency bonds 4,743 — 4,743 — Total short-term investments at fair value 32,773 14,826 17,947 — Total assets at fair value $ 45,361 $ 25,587 $ 19,774 $ — December 31, 2023 Fair Cost Amounts Recognized in Accumulated Other Comprehensive Loss Unrealized Gains Unrealized Losses (in thousands) Available-for-sale securities: U.S. Treasury securities $ 14,826 $ 14,820 $ 6 $ — Commercial paper and corporate bonds 13,204 13,197 9 ( 2 ) U.S. government agency bonds 4,743 4,745 — ( 2 ) Total available-for-sale securities at fair value $ 32,773 $ 32,762 $ 15 $ ( 4 )
Summary of Short-Term Investments	September 30, 2024 Fair Cost Amounts Recognized in Accumulated Other Comprehensive Loss Unrealized Gains Unrealized Losses (in thousands) Available-for-sale securities: U.S. treasury securities $ 1,487 $ 1,485 $ 2 $ — Commercial paper and corporate bonds 2,701 2,700 1 — Total available-for-sale securities at fair value $ 4,188 $ 4,185 $ 3 $ — December 31, 2023 Fair Cost Amounts Recognized in Accumulated Other Comprehensive Loss Unrealized Gains Unrealized Losses (in thousands) Available-for-sale securities: U.S. Treasury securities $ 14,826 $ 14,820 $ 6 $ — Commercial paper and corporate bonds 13,204 13,197 9 ( 2 ) U.S. government agency bonds 4,743 4,745 — ( 2 ) Total available-for-sale securities at fair value $ 32,773 $ 32,762 $ 15 $ ( 4 )

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-Based Compensation Expense	The following tables present the Company’s stock-based compensation for stock-settled awards by type (i.e., stock options and restricted stock units (“RSUs”) granted under the Company’s incentive plans, and rights to purchase shares of common stock issued under the Company’s Employee Stock Purchase Plan (“ESPP”) and financial statement lines included in the accompanying unaudited condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30: Three months ended September 30, Nine months ended September 30, 2024 2023 2024 2023 (in thousands) Options $ 233 $ 645 $ 880 $ 2,233 RSUs 397 1,094 3,343 3,389 ESPP — 45 — 163 Total stock-based compensation expense $ 630 $ 1,784 $ 4,223 $ 5,785 Three months ended September 30, 2024 2023 Continuing operations Discontinued operations Total Continuing operations Discontinued operations Total (in thousands) Cost of sales $ 14 $ — $ 14 $ 44 $ 10 $ 54 Selling and marketing 47 — 47 550 6 556 General and administrative 539 — 539 1,010 19 1,029 Research and development 30 — 30 136 9 145 Total stock-based compensation expense $ 630 $ — $ 630 $ 1,740 $ 44 $ 1,784 Nine months ended September 30, 2024 2023 Continuing operations Discontinued operations Total Continuing operations Discontinued operations Total (in thousands) Cost of sales $ 324 $ 79 $ 403 $ 262 $ 31 $ 293 Selling and marketing 838 59 897 1,698 18 1,716 General and administrative 2,141 140 2,281 3,156 55 3,211 Research and development 551 91 642 538 27 565 Total stock-based compensation expense $ 3,854 $ 369 $ 4,223 $ 5,654 $ 131 $ 5,785
Schedule of Unamortized Compensation Cost and Weighted Average Service Period of Unvested Outstanding Awards	T he following table presents the unamortized compensation cost and weighted average service period of all unvested outstanding awards as of September 30, 2024. Unamortized Compensation Costs Weighted Average Service Period (in thousands) (years) Options $ 660 0.75 RSUs 2,978 3.28 Total unamortized compensation cost $ 3,638
Summary of Stock Option Activity under Incentive Plans	T he following table summarizes stock option activity under the Company’s incentive plans: Number Weighted Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value (in years) (in thousands) Options outstanding, December 31, 2023 11,786 $ 571.27 6.3 $ — Forfeited/Expired ( 3,670 ) Options outstanding, September 30, 2024 8,116 $ 592.24 5.2 $ — Options vested and exercisable, September 30, 2024 7,600 $ 559.60 5.1 $ —
Summary of Non Vested Stock Options	The following table summarizes the non-vested stock options that were outstanding as of September 30, 2024 and December 31, 2023: Number of Shares Weighted Non-vested Options, December 31, 2023 2,217 $ 1,045.01 Non-vested Options, September 30, 2024 505 $ 1,736.21
Summary of RSU Activity under Incentive Plans	T he following table summarizes RSU activity under the Company’s incentive plans: Number Weighted RSUs outstanding, December 31, 2023 16,593 $ 517.03 Granted 29,194 $ 7.98 Vested ( 6,245 ) $ 570.64 Forfeited ( 4,120 ) $ 502.49 RSUs outstanding, September 30, 2024 35,422 $ 87.71

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Summary of Future Minimum Lease Payments	Future minimum lease payments under these leases are as follows: Lease Amounts (in thousands) 2024 (remaining three months) $ 202 2025 991 2026 938 2027 480 2028 122 Total future minimum lease payments 2,733 Less: Imputed Interest ( 279 ) Present value of operating lease liabilities $ 2,454 Less: Current portion 884 Long-term operating lease liabilities $ 1,570 Weighted average remaining lease term in years 2.84 Weighted average discount rate 8.10 %
Components of Lease Expense and Related Cash Flows	The components of lease expense and related cash flows were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Rent expense $ 297 $ 373 $ 969 $ 1,140 Variable lease costs 48 17 49 81 Total $ 345 $ 390 $ 1,018 $ 1,221 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands) Cost of sales $ 59 $ 67 $ 189 $ 205 General and administrative 286 323 829 1,016 Total $ 345 $ 390 $ 1,018 $ 1,221 Cash paid for operating leases $ 310 $ 382 $ 1,008 $ 1,140

Term Loan (Tables)

Term Loan (Tables)	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Schedule of Future Principal Repayments of Term Loan	Pursuant to the Third Amendment, future principal repayments and the net carrying value of the Perceptive Loan as of September 30, 2024, are as follows: Principal (in thousands) Remaining 3 months of 2024 $ 2,700 2025 10,800 2026 4,300 Total principal payment 17,800 Debt discounts ( 916 ) Net carrying value $ 16,884
Schedule of Future Minimum Revenue Thresholds	The Amended Perceptive Loan Agreement includes financial covenants that require the Company to (i) maintain, at all times, a minimum aggregate balance of $ 3.0 million in cash in one or more controlled accounts, and (ii) pursuant to the Third Amendment, satisfy certain minimum revenue thresholds, measured for the consecutive 12-month periods ending on each calendar quarter-end until September 30, 2026 as follows: For 12-month Period Ending Revenue (in thousands) September 30, 2024 $ 33,000 December 31, 2024 $ 31,500 March 31, 2025 $ 31,000 June 30, 2025 $ 33,000 September 30, 2025 $ 35,935 December 31, 2025 $ 40,160 March 31, 2026 $ 44,950 June 30, 2026 $ 51,500

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 (in thousands, except shares and per share data) (in thousands, except shares and per share data) Numerator: Loss from continuing operations, net of tax $ ( 7,536 ) $ ( 17,449 ) $ ( 27,171 ) $ ( 51,188 ) Income from discontinued operations, net of tax — 469 5,508 1,147 Net loss $ ( 7,536 ) $ ( 16,980 ) $ ( 21,663 ) $ ( 50,041 ) Denominator: Weighted-average shares outstanding – basic and diluted 477,857 471,427 475,188 469,934 Net loss per share – basic and diluted $ ( 15.77 ) $ ( 36.02 ) $ ( 45.59 ) $ ( 106.49 )

Organization and Basis of Pre_2

Organization and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
	Oct. 18, 2024 $ / shares shares	Jun. 10, 2024	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Segment shares	Sep. 30, 2023 USD ($)	Nov. 07, 2024 USD ($)	Jun. 04, 2024 $ / shares	Dec. 31, 2023 USD ($) shares
Organization And Basis Of Presentation [Line Items]
Cash and cash equivalents and short-term investments			$ 17,300		$ 17,300
Cash and cash equivalents			13,096		13,096				$ 14,009
Accumulated deficit			(451,676)		(451,676)				$ (430,013)
Net loss			(7,536)	$ (17,449)	(27,171)	$ (51,188)
Cash and cash equivalents used in operations					21,718	$ 36,557
Gain on sale of discontinued operations, net of tax					5,703
Principal repayment					22,200
Principal payments on outstanding borrowings			$ 15,000		$ 15,000
Operating and Reportable segments | Segment					2
Common stock, authorized | shares			500,000,000		500,000,000				500,000,000
Minimum market capitalization							$ 5,000
Maximum Market Capitalization			$ 5,000		$ 5,000
Stock bid price | $ / shares								$ 0.1
Reverse stock split ratio					0.005
Term Loan
Organization And Basis Of Presentation [Line Items]
Principal outstanding			17,800		$ 17,800
Software
Organization And Basis Of Presentation [Line Items]
Substantial assets			$ 0		0
Substantial operations					$ 0
Minimum
Organization And Basis Of Presentation [Line Items]
Reverse stock split ratio		0.1
Maximum
Organization And Basis Of Presentation [Line Items]
Reverse stock split ratio		0.005
Subsequent Event
Organization And Basis Of Presentation [Line Items]
Per share closing price | $ / shares	$ 5
Common stock, authorized | shares	500,000,000
Reverse stock split ratio	0.005

Summary Accounting Policies a_4

Summary Accounting Policies and Recent Accounting Pronouncements - Additional Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($) Customer	Sep. 30, 2023 Customer	Sep. 30, 2024 USD ($) Customer	Sep. 30, 2023 USD ($) Customer
Summary Of Accounting Policies [Line Items]
Revenue, practical expedient, incremental cost of obtaining contract [true false]			true
Revenue recognized			$ 0.5	$ 0.3
Allowance for credit loss	$ 0.3		$ 0.3
Customer Concentration Risk | Sales
Summary Of Accounting Policies [Line Items]
Number of customer accounted for sales | Customer	0	0	0	0
GentleWave Systems | Maximum
Summary Of Accounting Policies [Line Items]
Standard product warranty period			2 years	2 years

Summary Accounting Policies a_5

Summary Accounting Policies and Recent Accounting Pronouncements - Summary of Balances of Contract Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Summary Of Accounting Policies [Line Items]
Less: long-term portion	$ 230	$ 302
Contract liabilities – current	917	618
Extended Service Contracts
Summary Of Accounting Policies [Line Items]
Total contract liabilities	$ 1,147	$ 920

Summary Accounting Policies a_6

Summary Accounting Policies and Recent Accounting Pronouncements - Schedule of Revenues Disaggregated by Segment and Timing of Goods and Services Transferred (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Summary Of Accounting Policies [Line Items]
Total revenue	$ 8,036	$ 8,163	$ 23,397	$ 25,604
Product | Point in Time
Summary Of Accounting Policies [Line Items]
Total revenue	7,662	7,934	22,333	25,075
Product | Over Time
Summary Of Accounting Policies [Line Items]
Total revenue	$ 374	$ 229	$ 1,064	$ 529

Summary Accounting Policies a_7

Summary Accounting Policies and Recent Accounting Pronouncements - Schedule of Reconciliation of Change in Estimated Warranty (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Balance at beginning of period	$ 754	$ 1,579	$ 1,269	$ 1,930
Provision for warranties issued	177	170	620	570
Changes in estimate of pre-existing warranty			(112)
Warranty costs incurred	(316)	(384)	(1,162)	(1,135)
Balance at end of period	615	1,365	615	1,365
Current portion	574	1,228	574	1,228
Non-current portion	41	137	41	137
Total	$ 615	$ 1,365	$ 615	$ 1,365

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - Disposed of by Sale - TDO Software, Inc. - USD ($)		3 Months Ended		9 Months Ended
	Mar. 01, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale consideration	$ 16,000,000
Sale consideration amount received	15,000,000
Sale consideration due	$ 1,000,000
Balance amount receivable period	12 months
Depreciation and amortization, discontinued operations		$ 0	$ 100,000	$ 60,000	$ 400,000
Capital expenditure, discontinued operations		$ 0	$ 0	$ 0	$ 0

Discontinued Operations - Summa

Discontinued Operations - Summary Of Statements of Operations and Comprehensive Loss From Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Revenue	$ 2,243	$ 1,478	$ 6,569
Cost of sales	681	511	2,056
Gross profit	1,562	967	4,513
General and administrative	398	524	1,254
Selling and marketing	197	162	535
Research and development	498	476	1,599
Income (loss) from discontinued operations, net of tax	469	(195)	1,125
Other income			22
Gain on sale of discontinued operations, net of tax		5,703
Net income from discontinued operations	$ 469	$ 5,508	$ 1,147

Discontinued Operations - Sum_2

Discontinued Operations - Summary Of Assets And Liabilities Of Discontinued Operations (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Current assets	$ 1,000	$ 656
Non-current assets:
Intangible assets, net		661
Goodwill		8,454
Other		482
Total assets of discontinued operations	$ 1,000	10,253
Current liabilities:
Accounts payable		34
Accrued expenses		194
Accrued compensation		345
Operating lease liabilities		127
Total liabilities of discontinued operations		$ 700

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 5,693	$ 6,450
Work in process	230	278
Finished goods	5,564	4,346
Total inventory	$ 11,487	$ 11,074

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Reserve for excess and obsolete inventory	$ 1	$ 1	$ 1.7	$ 0.8
Charge related to phasing out legacy procedure instruments	$ 0.1	$ 0.3	1.2
Excess and obsolete inventory			$ 0.6

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets:
Total assets at fair value	$ 4,188	$ 32,773
Investment, Type [Extensible Enumeration]	Short-Term Investments	Short-Term Investments
U.S. Treasury Securities
Assets:
Total assets at fair value	$ 1,487	$ 14,826
Commercial Paper and Corporate Bonds
Assets:
Total assets at fair value	2,701	13,204
U.S. Government Agency Bonds
Assets:
Total assets at fair value		4,743
Fair Value Measurements Recurring Basis
Assets:
Total cash equivalents at fair value	12,539	12,588
Total assets at fair value	16,727	45,361
Fair Value Measurements Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total cash equivalents at fair value	12,539	10,761
Total assets at fair value	14,026	25,587
Fair Value Measurements Recurring Basis | Significant Other Observable Inputs (Level 2)
Assets:
Total cash equivalents at fair value		1,827
Total assets at fair value	2,701	19,774
Fair Value Measurements Recurring Basis | Short-Term Investments
Assets:
Total assets at fair value	4,188	32,773
Fair Value Measurements Recurring Basis | Short-Term Investments | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets at fair value	1,487	14,826
Fair Value Measurements Recurring Basis | Short-Term Investments | Significant Other Observable Inputs (Level 2)
Assets:
Total assets at fair value	2,701	17,947
Fair Value Measurements Recurring Basis | Money Market Funds
Assets:
Total cash equivalents at fair value	11,789	10,761
Fair Value Measurements Recurring Basis | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total cash equivalents at fair value	11,789	10,761
Fair Value Measurements Recurring Basis | Corporate Bonds
Assets:
Total cash equivalents at fair value		1,827
Fair Value Measurements Recurring Basis | Corporate Bonds | Significant Other Observable Inputs (Level 2)
Assets:
Total cash equivalents at fair value		1,827
Fair Value Measurements Recurring Basis | U.S. Treasury Securities
Assets:
Total cash equivalents at fair value	750
Total assets at fair value	1,487	14,826
Fair Value Measurements Recurring Basis | U.S. Treasury Securities | Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total cash equivalents at fair value	750
Total assets at fair value	1,487	14,826
Fair Value Measurements Recurring Basis | Commercial Paper and Corporate Bonds
Assets:
Total assets at fair value	2,701	13,204
Fair Value Measurements Recurring Basis | Commercial Paper and Corporate Bonds | Significant Other Observable Inputs (Level 2)
Assets:
Total assets at fair value	$ 2,701	13,204
Fair Value Measurements Recurring Basis | U.S. Government Agency Bonds
Assets:
Total cash equivalents at fair value		4,743
Fair Value Measurements Recurring Basis | U.S. Government Agency Bonds | Significant Other Observable Inputs (Level 2)
Assets:
Total cash equivalents at fair value		$ 4,743

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Short-Term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Available-for-sale securities:
Fair Value	$ 4,188	$ 32,773
Cost Basis	4,185	32,762
Amounts Recognized in Accumulated Other Comprehensive Loss, Unrealized Gains	3	15
Amounts Recognized in Accumulated Other Comprehensive Loss, Unrealized Losses		(4)
U.S. Treasury Securities
Available-for-sale securities:
Fair Value	1,487	14,826
Cost Basis	1,485	14,820
Amounts Recognized in Accumulated Other Comprehensive Loss, Unrealized Gains	2	6
Amounts Recognized in Accumulated Other Comprehensive Loss, Unrealized Losses		0
Commercial Paper and Corporate Bonds
Available-for-sale securities:
Fair Value	2,701	13,204
Cost Basis	2,700	13,197
Amounts Recognized in Accumulated Other Comprehensive Loss, Unrealized Gains	$ 1	9
Amounts Recognized in Accumulated Other Comprehensive Loss, Unrealized Losses		(2)
U.S. Government Agency Bonds
Available-for-sale securities:
Fair Value		4,743
Cost Basis		4,745
Amounts Recognized in Accumulated Other Comprehensive Loss, Unrealized Losses		$ (2)

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - $ / shares	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Minimum
Class Of Stock [Line Items]
Warrants expiration date	2027-06
Maximum
Class Of Stock [Line Items]
Warrants expiration date	2031-08
Warrants with Exercise Price of $2,400 Per Share
Class Of Stock [Line Items]
Number of warrants issued	1,518
Warrant exercise price per share	$ 2,400
Number of warrants outstanding	1,518
Perceptive Credit Holdings III, LP | Warrants with Exercise Price of $2,190 Per Share
Class Of Stock [Line Items]
Number of warrants issued		95
Warrant exercise price per share		$ 2,190
Number of warrants outstanding		95
Perceptive Credit Holdings III, LP | Warrants with Exercise Price of $2,400 Per Share
Class Of Stock [Line Items]
Number of warrants issued		1,518
Warrant exercise price per share		$ 2,400
Number of warrants outstanding		1,518
Prefunded Warrants
Class Of Stock [Line Items]
Number of warrants issued	157,200
Number of warrants outstanding	59,300

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 630	$ 1,784	$ 4,223	$ 5,785
Continuing operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	630	1,740	3,854	5,654
Discontinued operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		44	369	131
Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	233	645	880	2,233
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	397	1,094	3,343	3,389
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		45		163
Cost of Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	14	54	403	293
Cost of Sales | Continuing operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	14	44	324	262
Cost of Sales | Discontinued operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		10	79	31
Selling and marketing
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	47	556	897	1,716
Selling and marketing | Continuing operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	47	550	838	1,698
Selling and marketing | Discontinued operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		6	59	18
General and administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	539	1,029	2,281	3,211
General and administrative | Continuing operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	539	1,010	2,141	3,156
General and administrative | Discontinued operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		19	140	55
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	30	145	642	565
Research and Development | Continuing operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 30	136	551	538
Research and Development | Discontinued operations
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense		$ 9	$ 91	$ 27

Stock Based Compensation - Sc_2

Stock Based Compensation - Schedule of Unamortized Compensation Cost and Weighted Average Service Period of Unvested Outstanding Awards (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized Compensation Costs	$ 3,638
Options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized Compensation Costs	$ 660
Weighted Average Service Period	9 months
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized Compensation Costs	$ 2,978
Weighted Average Service Period	3 years 3 months 10 days

Stock Based Compensation - Summ

Stock Based Compensation - Summary of Stock Option Activity under Incentive Plans (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Number of Shares, Options Outstanding, Beginning Balance	11,786
Number of Shares, Forfeited/Expired	(3,670)
Number of Shares, Options Outstanding, Ending Balance	8,116	11,786
Number of Shares, Options vested and exercisable at September 30, 2024	7,600
Weighted Average Exercise Price Per Share, Options Outstanding,December 31, 2023	$ 571.27
Weighted Average Exercise Price Per Share, Ending Balance	592.24	$ 571.27
Weighted Average Exercise Price Vested and exercisable at , September 30, 2024	$ 559.6
Weighted-Average Remaining Contractual Life (Years) Outstanding	5 years 2 months 12 days	6 years 3 months 18 days
Weighted-Average Remaining Contractual Life (in years) Options vested and exercisable , September 30, 2024	5 years 1 month 6 days

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, options granted (shares)			0
Fair value of shares vested			$ 2,800	$ 2,100
Weighted-average grant-date fair value of options granted				$ 0.83
Unamortized compensation expense	$ 3,638		3,638
Compensation cost recognized	630	$ 1,784	4,223	$ 5,785
Cost of Sales
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	14	54	403	293
Selling and marketing
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	47	556	897	1,716
General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	539	1,029	2,281	3,211
Research and Development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	30	145	642	565
Continuing operations
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	630	1,740	3,854	5,654
Continuing operations | Cost of Sales
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	14	44	324	262
Continuing operations | Selling and marketing
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	47	550	838	1,698
Continuing operations | General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	539	1,010	2,141	3,156
Continuing operations | Research and Development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized	30	136	551	538
Discontinued operations
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized		44	369	131
Discontinued operations | Cost of Sales
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized		10	79	31
Discontinued operations | Selling and marketing
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized		6	59	18
Discontinued operations | General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized		19	140	55
Discontinued operations | Research and Development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Compensation cost recognized		9	$ 91	27
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares vested			6,245
Number of shares vested			2,947
Unamortized compensation expense	2,978		$ 2,978
Compensation cost recognized	397	$ 1,094	3,343	$ 3,389
RSUs | Continuing operations
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized compensation expense	1,600		1,600
RSUs | Continuing operations | Cost of Sales
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized compensation expense	300		300
RSUs | Continuing operations | Selling and marketing
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized compensation expense	600		600
RSUs | Continuing operations | General and administrative
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized compensation expense	200		200
RSUs | Continuing operations | Research and Development
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized compensation expense	400		400
RSUs | Discontinued operations
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unamortized compensation expense	$ 300		$ 300

Stock Based Compensation - Su_2

Stock Based Compensation - Summary of Non Vested Options (Details) - Options	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Non-vested Options, December 31, 2023 | shares	2,217
Number of Shares, Non-vested Options, September 30, 2024 | shares	505
Weighted Average Grant Date Fair Value, Non-vested Options, December 31, 2023 | $ / shares	$ 1,045.01
Weighted Average Grant Date Fair Value, Non-vested Options,September 30, 2024 | $ / shares	$ 1,736.21

Stock Based Compensation - Su_3

Stock Based Compensation - Summary of RSU Activity under Incentive Plans (Details) - RSUs	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, RSUs outstanding, Beginning Balance | shares	16,593
Number of Shares, Granted | shares	29,194
Number of Shares, Vested | shares	(6,245)
Number of Shares, Forfeited | shares	(4,120)
Number of Shares, RSUs outstanding, Ending Balance | shares	35,422
Weighted Average Grant Date Fair Value, RSUs outstanding, Beginning Balance | $ / shares	$ 517.03
Weighted Average Grant Date Fair Value, Granted | $ / shares	7.98
Weighted Average Exercise Date Fair Value, Exercised | $ / shares	570.64
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	502.49
Weighted Average Grant Date Fair Value, RSUs outstanding, Ending Balance | $ / shares	$ 87.71

Leases - Additional Information

Leases - Additional Information (Details)	9 Months Ended
	Sep. 30, 2024
Leases [Abstract]
Operating lease description	The Company leases office space under operating leases with expirations ranging from March 2025 to March 2028, some of which include rent escalations or an option to extend the lease for up to three years per renewal. The exercise of lease renewal options is at the sole discretion of the Company.
Operating lease renewal term	3 years
Lessee, Operating Lease, Existence of Option to Extend [true false]	true
Operating lease, not yet commenced, description	the Company has not entered into any new leases that would entitle the Company to significant rights or create additional obligations.

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases [Abstract]
2024 (remaining three months)	$ 202
2025	991
2026	938
2027	480
2028	122
Total future minimum lease payments	2,733
Less: Imputed Interest	(279)
Present value of operating lease liabilities	2,454
Less: Current portion	884	$ 1,250
Long-term operating lease liabilities	$ 1,570	$ 1,423
Weighted average remaining lease term in years	2 years 10 months 2 days
Weighted average discount rate	8.10%

Leases - Components of Lease Ex

Leases - Components of Lease Expense and Related Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Lessee, Lease, Description [Line Items]
Rent expense	$ 297	$ 373	$ 969	$ 1,140
Variable lease costs	48	17	49	81
Lease costs	345	390	1,018	1,221
Cash paid for operating leases	310	382	1,008	1,140
Cost of Sales
Lessee, Lease, Description [Line Items]
Lease costs	59	67	189	205
General and administrative
Lessee, Lease, Description [Line Items]
Lease costs	$ 286	$ 323	$ 829	$ 1,016

Term Loan - Additional Informat

Term Loan - Additional Information (Details) - USD ($) $ in Thousands		9 Months Ended		12 Months Ended
	Mar. 01, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024
Debt Instrument [Line Items]
Principal repayment		$ 22,200
Revenue				$ 36,500
Cash and cash equivalents and short-term investments		17,300		17,300
Amended Perceptive Loan Agreement
Debt Instrument [Line Items]
Aggregate minimum cash balance		$ 3,000		$ 3,000
Amended Perceptive Loan Agreement | Prepayments Made After August 23, 2025
Debt Instrument [Line Items]
Debt instrument prepayment premium percentage		0%		0%
Third Amendment
Debt Instrument [Line Items]
Debt instrument covenant description		Pursuant to the Third Amendment, the lender also waived the covenant requiring the absence of any “going concern” or like qualification or exception or any qualification or exception as to the scope of the audit, solely with respect to the fiscal year ending on December 31, 2023.Failure to satisfy any covenants would constitute an event of default under the Amended Perceptive Loan Agreement. In the event of an event of default, the lender may terminate its commitments and declare all amounts outstanding under the Amended Perceptive Loan Agreement immediately due and payable, together with accrued interest and all fees and other obligations. The amount of such repayment will include payment of any prepayment premium applicable due to the time of such payment. In addition, upon the occurrence and during the continuance of any event of default, the applicable margin will increase by 3.00% per annum to 12.25%.
Principal repayment	$ 15,000
Amortization payment	$ 1,800
Frequency of periodic payments	monthly
Debt instrument periodic payment	$ 900
Payment commencement date	Apr. 30, 2024
Unamortized debt issuance cost expensed	$ 1,000
Minimum | Amended Perceptive Loan Agreement
Debt Instrument [Line Items]
Effective interest rate percentage		3%		3%
Minimum | Amended Perceptive Loan Agreement | Prepayments Made After August 23, 2022 and Before August 23, 2025
Debt Instrument [Line Items]
Debt instrument prepayment premium percentage		1%		1%
Maximum | Amended Perceptive Loan Agreement
Debt Instrument [Line Items]
Effective interest rate percentage		12.25%		12.25%
Maximum | Amended Perceptive Loan Agreement | Prepayments Made After August 23, 2022 and Before August 23, 2025
Debt Instrument [Line Items]
Debt instrument prepayment premium percentage		7%		7%
SOFR Plus 2% | Minimum | Amended Perceptive Loan Agreement
Debt Instrument [Line Items]
Additional interest rate on borrowing		2%	2%
Interest rate margin on borrowings		9.25%	9.25%
Perceptive Credit Holdings III, LP
Debt Instrument [Line Items]
Effective interest rate percentage		21.10%	17.39%	21.10%

Term Loan - Schedule of Future

Term Loan - Schedule of Future Principal Repayments of Term Loan (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Debt Disclosure [Abstract]
Remaining 3 months of 2024	$ 2,700
2025	10,800
2026	4,300
Total	17,800
Debt discounts	(916)
Net carrying value	$ 16,884

Term Loan - Schedule of Futur_2

Term Loan - Schedule of Future Minimum Revenue Threshold (Details) - Third Amendment - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2024
Debt Instrument [Line Items]
Minimum Revenue Thresholds Amount								$ 33,000
Forecast
Debt Instrument [Line Items]
Minimum Revenue Thresholds Amount	$ 51,500	$ 44,950	$ 40,160	$ 35,935	$ 33,000	$ 31,000	$ 31,500

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	9 Months Ended
	Sep. 30, 2024
Internal Revenue Code | R&D credit carryforwards
Income Tax Contingency [Line Items]
Ownership change percentage	50%
Federal
Income Tax Contingency [Line Items]
Open tax year	2021 2022 2023
State
Income Tax Contingency [Line Items]
Open tax year	2020 2021 2022 2023

Segment Information - Additiona

Segment Information - Additional Information (Details) - Software $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Segment Reporting Information [Line Items]
Substantial assets	$ 0
Substantial operations	$ 0

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Numerator:
Loss from continuing operations, net of tax	$ (7,536)			$ (17,449)			$ (27,171)	$ (51,188)
Income from discontinued operations, net of tax				469			5,508	1,147
Net loss	$ (7,536)	$ (7,365)	$ (6,762)	$ (16,980)	$ (17,690)	$ (15,371)	$ (21,663)	$ (50,041)
Denominator:
Weighted-average shares outstanding - basic	477,857			471,427			475,188	469,934
Weighted-average shares outstanding - diluted	477,857			471,427			475,188	469,934
Net loss per share - basic	$ (15.77)			$ (36.02)			$ (45.59)	$ (106.49)
Net loss per share - diluted	$ (15.77)			$ (36.02)			$ (45.59)	$ (106.49)

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) $ in Millions					3 Months Ended	9 Months Ended
	Nov. 04, 2024 USD ($)	Oct. 18, 2024 shares	Sep. 30, 2024 USD ($) shares	Jun. 10, 2024	Sep. 30, 2024 USD ($) shares	Sep. 30, 2024 USD ($) shares	Dec. 31, 2023 shares
Subsequent Event [Line Items]
Common stock, shares authorized | shares			500,000,000		500,000,000	500,000,000	500,000,000
Reverse stock split ratio						0.005
Biolase, Inc.
Subsequent Event [Line Items]
Downward working capital adjustment			$ 14
Transaction and financing expenses					$ 0.9	$ 0.9
Maximum
Subsequent Event [Line Items]
Reverse stock split ratio				0.005
Subsequent Event
Subsequent Event [Line Items]
Common stock, shares authorized | shares		500,000,000
Reverse stock split ratio		0.005
Subsequent Event | Biolase, Inc.
Subsequent Event [Line Items]
Percentage of purchase price	10%
Percentage of break up fee payable	3%
Subsequent Event | Maximum | Biolase, Inc.
Subsequent Event [Line Items]
Reimbursement expenses	$ 0.6